The prognostic value of mid-regional pro-adrenomedullin in the evaluation of acute dyspnea

References

• Kunitoh H, Watanabe K, Sajima Y. Dyspnea in acute bronchial asthma in an emergency room. Ann Allergy. 1994;72(3):250–254.
   PubMedGoogle Scholar
• Kunitoh H, Nagatomo A, Okamoto H, et al. Predicting the need for hospital admission in patients with acute bronchial asthma. J Asthma. 1996;33(2):105–112.
   PubMed Web of Science ®Google Scholar
• Gruenberger J-B, Vietri J, Keininger DL, et al. Greater dyspnea is associated with lower health-related quality of life among European patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:937–944.
   PubMed Web of Science ®Google Scholar
• Pang PS, Collins SP, Gheorghiade M, et al. Acute dyspnea and decompensated heart failure. Cardiol Clin. 2018;36(1):63–72.
   PubMed Web of Science ®Google Scholar
• Lenferink A, Brusse-Keizer M, van der Valk PD, et al. Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;8:CD011682.
   Google Scholar
• Ji Q-Y, Wang M-F, Su C-M, et al. Clinical symptoms and related risk factors in pulmonary embolism patients and cluster analysis based on these symptoms. Sci Rep. 2017;7(1):14887.
   PubMedGoogle Scholar
• Ruan W, Lim SH, Ding ZP, et al. Prevalence, presentation, and outcome of heart failure with preserved ejection fraction among patients presenting with undifferentiated dyspnoea to the emergency room: a 10-year analysis from a tertiary centre. Ann Acad Med Singapore. 2016;45(1):18–26.
   PubMed Web of Science ®Google Scholar
• Fernández-Susavila H, Rodríguez‐Yáñez M, Dopico‐López A, et al. Heads and tails of natriuretic peptides: neuroprotective role of brain natriuretic peptide. J Am Heart Assoc. 2017;6(12):e007329.
   PubMed Web of Science ®Google Scholar
• Rasmussen, MB, Stengaard C, Sørensen JT, et al. Predictive value of routine point-of-care cardiac troponin T measurement for prehospital diagnosis and risk-stratification in patients with suspected acute myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2017;6(8):2048872617745893.
   Google Scholar
• Choi JJ, McCarthy MW. Novel applications for serum procalcitonin testing in clinical practice. Expert Rev Mol Diagn. 2017;18(1):27–34.
   PubMed Web of Science ®Google Scholar
• Douketis JD, Crowther MA, Stanton EB, et al. Elevated cardiac troponin levels in patients with submassive pulmonary embolism. Arch Intern Med. 2002;162(1):79–81.
   PubMedGoogle Scholar
• Bajaj A, Saleeb M, Rathor P, et al. Prognostic value of troponins in acute nonmassive pulmonary embolism: a meta-analysis. Heart Lung. 2015;44(4):327–334.
   PubMed Web of Science ®Google Scholar
• Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation. 2007;116(4):427–433.
   PubMed Web of Science ®Google Scholar
• Jiménez D, Uresandi F, Otero R, et al. Troponin-based risk stratification of patients with acute nonmassive pulmonary embolism: systematic review and metaanalysis. Chest. 2009;136(4):974–982.
   PubMed Web of Science ®Google Scholar
• Peacock WF, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008;358(20):2117–2126.
   PubMed Web of Science ®Google Scholar
• Pedowska-Włoszek J, Kostrubiec M, Kurnicka K, et al. Midregional proadrenomedullin (MR-proADM) in the risk stratification of patients with acute pulmonary embolism. Thromb Res. 2013;132(5):506–510.
   PubMed Web of Science ®Google Scholar
• Morbach C, Marx A, Kaspar M, et al. Prognostic potential of midregional pro-adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides. Eur J Heart Fail. 2017;19(9):1166–1175.
   PubMed Web of Science ®Google Scholar
• Dres M, Hausfater P, Foissac F, et al. Mid-regional pro-adrenomedullin and copeptin to predict short-term prognosis of COPD exacerbations: a multicenter prospective blinded study. Int J Chron Obstruct Pulmon Dis. 2017;12:1047–1056.
   PubMed Web of Science ®Google Scholar
• Lundberg OH, Cazalis M-A, Pachot A, et al. Adrenomedullin and endothelin-1 are associated with myocardial injury and death in septic shock patients. Crit Care. 2016;20(1):178.
   PubMedGoogle Scholar
• Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341(8):577–585.
   PubMed Web of Science ®Google Scholar
• Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993;192(2):553–560.
   PubMed Web of Science ®Google Scholar
• Kitamura K, Sakata J, Kangawa K, et al. Cloning and characterization of cDNA encoding a precursor for human adrenomedullin. Biochem Biophys Res Commun. 1993;194(2):720–725.
   PubMed Web of Science ®Google Scholar
• Nishikimi T, Kuwahara K, Nakagawa Y, et al. Adrenomedullin in cardiovascular disease: a useful biomarker, its pathological roles and therapeutic application. Curr Protein Pept Sci. 2013;14(4):256–267.
   PubMed Web of Science ®Google Scholar
• Vari RC, Adkins SD, Samson WK. Renal effects of adrenomedullin in the rat. Proc Soc Exp Biol Med. 1996;211(2):178–183.
   PubMed Web of Science ®Google Scholar
• Nagaya N, Nishikimi T, Horio T, et al. Cardiovascular and renal effects of adrenomedullin in rats with heart failure. Am J Physiol. 1999;276(1 Pt 2):R213–8.
   PubMedGoogle Scholar
• Nishikimi T, Karasawa T, Inaba C, et al. Effects of long-term intravenous administration of adrenomedullin (AM) plus hANP therapy in acute decompensated heart failure: a pilot study. Circ J. 2009;73(5):892–898.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Yoshida H, Makita S, et al. Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure. Circulation. 1997;95(5):1214–1221.
   PubMed Web of Science ®Google Scholar
• Nishikimi T, Matsuoka H. Cardiac adrenomedullin: its role in cardiac hypertrophy and heart failure. Curr Med Chem Cardiovasc Hematol Agents. 2005;3(3):231–242.
   PubMedGoogle Scholar
• Nishikimi T. Adrenomedullin in the kidney-renal physiological and pathophysiological roles. Curr Med Chem. 2007;14(15):1689–1699.
   PubMed Web of Science ®Google Scholar
• Valenzuela-Sánchez F, Li BT, Schindler K, et al. New role of biomarkers: mid-regional pro-adrenomedullin, the biomarker of organ failure. Ann Transl Med. 2016;4(17):329.
   PubMed Web of Science ®Google Scholar
• Struck J, Tao C, Morgenthaler NG, et al. Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients. Peptides. 2004;25(8):1369–1372.
   PubMed Web of Science ®Google Scholar
• Eto T. A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides. Peptides. 2001;22(11):1693–1711.
   PubMed Web of Science ®Google Scholar
• Nishio K, Akai Y, Murao Y, et al. Increased plasma concentrations of adrenomedullin correlate with relaxation of vascular tone in patients with septic shock. Crit Care Med. 1997;25(6):953–957.
   PubMed Web of Science ®Google Scholar
• Kitamura K, Ichiki Y, Tanaka M, et al. Immunoreactive adrenomedullin in human plasma. FEBS Lett. 1994;341(2–3):288–290.
   PubMed Web of Science ®Google Scholar
• Nishikimi T, Nakagawa Y. Adrenomedullin as a biomarker of heart failure. Heart Fail Clin. 2018;14(1):49–55.
   PubMed Web of Science ®Google Scholar
• Nishikimi T, Horio T, Kohmoto Y, et al. Molecular forms of plasma and urinary adrenomedullin in normal, essential hypertension and chronic renal failure. J Hypertens. 2001;19(4):765–773.
   PubMed Web of Science ®Google Scholar
• Meeran K, O’Shea D, Upton PD, et al. Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study. J Clin Endocrinol Metab. 1997;82(1):95–100.
   PubMed Web of Science ®Google Scholar
• Lewis LK, Smith MW, Yandle TG, et al. Adrenomedullin(1-52) measured in human plasma by radioimmunoassay: plasma concentration, adsorption, and storage. Clin Chem. 1998;44(3):571–577.
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Morgenthaler NG, Struck J, et al. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care. 2005;9(6):R816–24.
   PubMed Web of Science ®Google Scholar
• Nishikimi T, Kitamura K, Saito Y, et al. Clinical studies on the sites of production and clearance of circulating adrenomedullin in human subjects. Hypertension. 1994;24(5):600–604.
   PubMed Web of Science ®Google Scholar
• Minami J, Nishikimi T, Todoroki M, et al. Source of plasma adrenomedullin in patients with pheochromocytoma. Am J Hypertens. 2002;15(11):994–997.
   PubMed Web of Science ®Google Scholar
• Sugo S, Minamino N, Kangawa K, et al. Endothelial cells actively synthesize and secrete adrenomedullin. Biochem Biophys Res Commun. 1994;201(3):1160–1166.
   PubMed Web of Science ®Google Scholar
• Sugo S, Minamino N, Shoji H, et al. Production and secretion of adrenomedullin from vascular smooth muscle cells: augmented production by tumor necrosis factor-alpha. Biochem Biophys Res Commun. 1994;203(1):719–726.
   PubMed Web of Science ®Google Scholar
• Bahrmann P, Christ M, Hofner B, et al. Prognostic value of different biomarkers for cardiovascular death in unselected older patients in the emergency department. Eur Heart J Acute Cardiovasc Care. 2016;5(8):568–578.
   PubMed Web of Science ®Google Scholar
• Ara-Somohano C, Bonadona A, Carpentier F, et al. Evaluation of eight biomarkers to predict short-term mortality in patients with acute severe dyspnea. Minerva Anestesiol. 2017;83(8):824–835.
   PubMed Web of Science ®Google Scholar
• Hausfater P, Claessens Y-E, Martinage A, et al. Prognostic value of PCT, copeptin, MR-proADM, MR-proANP and CT-proET-1 for severe acute dyspnea in the emergency department: the BIODINER study. Biomarkers. 2017;22(1):28–34.
   PubMed Web of Science ®Google Scholar
• Möckel M, Searle J, Hartmann O, et al. Mid-regional pro-adrenomedullin improves disposition strategies for patients with acute dyspnoea: results from the BACH trial. Emerg Med J. 2013;30(8):633–637.
   PubMed Web of Science ®Google Scholar
• Nishikimi T, Saito Y, Kitamura K, et al. Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol. 1995;26(6):1424–1431.
   PubMed Web of Science ®Google Scholar
• Kato J, Kobayashi K, Etoh T, et al. Plasma adrenomedullin concentration in patients with heart failure. J Clin Endocrinol Metab. 1996;81(1):180–183.
   PubMed Web of Science ®Google Scholar
• Boyer B, Hart KW, Sperling MI, et al. Biomarker changes during acute heart failure treatment. Congest Heart Fail. 2012;18(2):91–97.
   PubMedGoogle Scholar
• Funke-Kaiser A, Havulinna AS, Zeller T, et al. Predictive value of midregional pro-adrenomedullin compared to natriuretic peptides for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort. Ann Med. 2014;46(3):155–162.
   PubMed Web of Science ®Google Scholar
• Gegenhuber A, Struck J, Dieplinger B, et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail. 2007;13(1):42–49.
   PubMed Web of Science ®Google Scholar
• Von Haehling S, Filippatos GS, Papassotiriou J, et al. Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail. 2010;12(5):484–491.
   PubMed Web of Science ®Google Scholar
• Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (biomarkers in acute heart failure) trial. J Am Coll Cardiol. 2010;55(19):2062–2076.
   PubMed Web of Science ®Google Scholar
• Maisel A, Mueller C, Nowak RM, et al. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (biomarkers in acute heart failure) trial. J Am Coll Cardiol. 2011;58(10):1057–1067.
   PubMed Web of Science ®Google Scholar
• Shah RV, Truong QA, Gaggin HK, et al. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J. 2012;33(17):2197–2205.
   PubMed Web of Science ®Google Scholar
• Xue Y, Taub P, Iqbal N, et al. Mid-region pro-adrenomedullin adds predictive value to clinical predictors and Framingham risk score for long-term mortality in stable outpatients with heart failure. Eur J Heart Fail. 2013;15(12):1343–1349.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Hausfater P, Amin D, et al. Biomarkers from distinct biological pathways improve early risk stratification in medical emergency patients: the multinational, prospective, observational TRIAGE study. Crit Care. 2015;19:377.
   PubMed Web of Science ®Google Scholar
• Bello S, Lasierra AB, Mincholé E, et al. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. Eur Respir J. 2012;39(5):1144–1155.
   PubMed Web of Science ®Google Scholar
• Brusse-Keizer M, Zuur-Telgen M, Van Der Palen J, et al. Adrenomedullin optimises mortality prediction in COPD patients. Respir Med. 2015;109(6):734–742.
   PubMed Web of Science ®Google Scholar
• Bernasconi M, Tamm M, Bingisser R, et al. Midregional proatrial natriuretic peptide predicts survival in exacerbations of COPD. Chest. 2011;140(1):91–99.
   PubMed Web of Science ®Google Scholar
• Meng D-Q, Li X-J, Song X-Y, et al. Diagnostic and prognostic value of plasma adrenomedullin in COPD exacerbation. Respir Care. 2014;59(10):1542–1549.
   PubMed Web of Science ®Google Scholar
• Stolz D, Christ-Crain M, Morgenthaler NG, et al. Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. Chest. 2008;134(2):263–272.
   PubMed Web of Science ®Google Scholar
• Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest. 2007;131(4):1058–1067.
   PubMed Web of Science ®Google Scholar
• Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–1012.
   PubMed Web of Science ®Google Scholar
• Stolz D, Kostikas K, Blasi F, et al. Adrenomedullin refines mortality prediction by the BODE index in COPD: the “BODE-A” index. Eur Respir J. 2014;43(2):397–408.
   PubMed Web of Science ®Google Scholar
• Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243–250.
   PubMed Web of Science ®Google Scholar
• Bauer TT, Ewig S, Marre R, et al. CRB-65 predicts death from community-acquired pneumonia. J Intern Med. 2006;260(1):93–101.
   PubMed Web of Science ®Google Scholar
• Aujesky D, Fine MJ. The pneumonia severity index: a decade after the initial derivation and validation. Clin Infect Dis. 2008;47(Suppl 3):S133–9.
   PubMedGoogle Scholar
• Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care. 2010;14(1):203.
   PubMed Web of Science ®Google Scholar
• Lim WS, Van Der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377–382.
   PubMed Web of Science ®Google Scholar
• Albrich WC, Hahn JA, Delwart E, et al. Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC Infect Dis. 2011;11:112.
   PubMed Web of Science ®Google Scholar
• Alan M, Grolimund E, Kutz A, et al. Clinical risk scores and blood biomarkers as predictors of long-term outcome in patients with community-acquired pneumonia: a 6-year prospective follow-up study. J Intern Med. 2015;278(2):174–184.
   PubMed Web of Science ®Google Scholar
• Legramante JM, Mastropasqua M, Susi B, et al. Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia in the Emergency Department compared to clinical severity scores PSI and CURB. PLoS One. 2017;12(11):e0187702.
   PubMed Web of Science ®Google Scholar
• Courtais C, Kuster N, Dupuy A-M, et al. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia. Am J Emerg Med. 2013;31(1):215–221.
   PubMed Web of Science ®Google Scholar
• Huang DT, Angus DC, Kellum JA, et al. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest. 2009;136(3):823–831.
   PubMed Web of Science ®Google Scholar
• España PP, Capelastegui A, Mar C, et al. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia. J Infect. 2015;70(5):457–466.
   PubMed Web of Science ®Google Scholar
• Liu D, Cornick JE, Harris SR, et al. Prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: a systematic review and meta-analysis. BMC Infect Dis. 2016;16:232.
   PubMed Web of Science ®Google Scholar
• Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370(15):1402–1411.
   PubMed Web of Science ®Google Scholar
• Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123(16):1788–1830.
   PubMed Web of Science ®Google Scholar
• Wu AH, Wu AHB, Jaffe AS, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem. 2007;53(12):2086–2096.
   PubMed Web of Science ®Google Scholar
• Vuilleumier N, Simona A, Méan M, et al. Comparison of cardiac and non-cardiac biomarkers for risk stratification in elderly patients with non-massive pulmonary embolism. PLoS One. 2016;11(5):e0155973.
   PubMed Web of Science ®Google Scholar
• Kutz A, Hausfater P, Amin D, et al. The TRIAGE-ProADM score for an early risk stratification of medical patients in the emergency department - development based on a multi-national, prospective, observational study. PLoS One. 2016;11(12):e0168076.
   PubMed Web of Science ®Google Scholar
• Travaglino F, Russo V, De Berardinis B, et al. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial. Am J Emerg Med. 2014;32(4):334–341.
   PubMed Web of Science ®Google Scholar
• Spoto S, Cella E, De Cesaris M, et al. Procalcitonin and Mr-Proadrenomedullin combination with sofa and qsofa scores for sepsis diagnosis and prognosis: a diagnostic algorithm. Shock. 2017. Epub ahead of print.
   PubMedGoogle Scholar
• Puskarich MA, Trzeciak S, Shapiro NI, et al. Outcomes of patients undergoing early sepsis resuscitation for cryptic shock compared with overt shock. Resuscitation. 2011;82(10):1289–1293.
   PubMed Web of Science ®Google Scholar
• Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589–1596.
   PubMed Web of Science ®Google Scholar
• Adams HP, Effron MB, Torner J, et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: abciximab in emergency treatment of stroke Trial (AbESTT-II). Stroke. 2008;39(1):87–99.
   PubMed Web of Science ®Google Scholar
• Cantor WJ, Fitchett D, Borgundvaag B, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med. 2009;360(26):2705–2718.
   PubMed Web of Science ®Google Scholar
• Gorissen C, Baumgarten R, De Groot M, et al. Analytical and clinical performance of three natriuretic peptide tests in the emergency room. Clin Chem Lab Med. 2007;45(5):678–684.
   PubMed Web of Science ®Google Scholar
• Geraci JM, Tsang W, Valdres RV, et al. Progressive disease in patients with cancer presenting to an emergency room with acute symptoms predicts short-term mortality. Support Care Cancer. 2006;14(10):1038–1045.
   PubMed Web of Science ®Google Scholar
• Taboulet P, Feugeas JP. [Acute dyspnea in the emergency room: the utility of troponin, natriuretic, procalcitonin and D-dimers]. Ann Biol Clin (Paris). 2005;63(4):377–384.
   PubMed Web of Science ®Google Scholar
• Al Shuaibi M, Bahu RR, Chaftari A-M, et al. Pro-adrenomedullin as a novel biomarker for predicting infections and response to antimicrobials in febrile patients with hematologic malignancies. Clin Infect Dis. 2013;56(7):943–950.
   PubMed Web of Science ®Google Scholar
• Travaglino F, Page K, Stein ES, et al. Utility of Procalcitonin (PCT) and Mid regional pro-Adrenomedullin (MR-proADM) in risk stratification of critically ill febrile patients in Emergency Department (ED). A comparison with APACHE II score. BMC Infect Dis. 2012;12:184.
   PubMed Web of Science ®Google Scholar
• Angeletti S, Battistoni F, Fioravanti M, et al. Procalcitonin and mid-regional pro-adrenomedullin test combination in sepsis diagnosis. Clin Chem Lab Med. 2013;51(5):1059–1067.
   PubMed Web of Science ®Google Scholar
• Pezzilli R, Barassi A, Pigna A, et al. Time course of proadrenomedullin in the early phase of septic shock. A comparative study with other proinflammatory proteins. Panminerva Med. 2012;54(3):211–217.
   PubMed Web of Science ®Google Scholar
• DE LA Torre-Prados MV, Garcia-DE LA Torre A, Enguix A, et al. Mid-regional pro-adrenomedullin as prognostic biomarker in septic shock. Minerva Anestesiol. 2016;82(7):760–766.
   PubMed Web of Science ®Google Scholar
• Enguix-Armada A, Escobar-Conesa R, García-De La Torre A, et al. Usefulness of several biomarkers in the management of septic patients: C-reactive protein, procalcitonin, presepsin and mid-regional pro-adrenomedullin. Clin Chem Lab Med. 2016;54(1):163–168.
   PubMed Web of Science ®Google Scholar
• Bustamante A, García-Berrocoso T, Penalba A, et al. Sepsis biomarkers reprofiling to predict stroke-associated infections. J Neuroimmunol. 2017;312:19–23.
   PubMed Web of Science ®Google Scholar
• Gille J, Ostermann H, Dragu A, et al. MR-proADM: a new biomarker for early diagnosis of sepsis in burned patients. J Burn Care Res. 2017;38(5):290–298.
   PubMed Web of Science ®Google Scholar
• Fedorowski A, Burri P, Struck J, et al. Novel cardiovascular biomarkers in unexplained syncopal attacks: the SYSTEMA cohort. J Intern Med. 2013;273(4):359–367.
   PubMed Web of Science ®Google Scholar
• Haaf P, Twerenbold R, Reichlin T, et al. Mid-regional pro-adrenomedullin in the early evaluation of acute chest pain patients. Int J Cardiol. 2013;168(2):1048–1055.
   PubMed Web of Science ®Google Scholar
• Tzikas S, Keller T, Ojeda FM, et al. MR-proANP and MR-proADM for risk stratification of patients with acute chest pain. Heart. 2013;99(6):388–395.
   PubMed Web of Science ®Google Scholar
• O’Malley RG, Bonaca MP, Scirica BM, et al. Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (metabolic efficiency with ranolazine for less ischemia in Non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36). J Am Coll Cardiol. 2014;63(16):1644–1653.
   PubMed Web of Science ®Google Scholar
• Khan SQ, O’Brien RJ, Struck J, et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol. 2007;49(14):1525–1532.
   PubMed Web of Science ®Google Scholar
• Acosta S, Gottsäter A, Engström G, et al. Circulating midregional proadrenomedullin and risk of incident abdominal aortic aneurysm: a prospective longitudinal cohort study. Angiology. 2017; 3319717723255. Epub ahead of print.
   Google Scholar
• Goliasch G, Bartko PE, Neuhold S, et al. Refining the prognostic impact of functional mitral regurgitation in chronic heart failure. Eur Heart J. 2017.
   Web of Science ®Google Scholar
• Page VJ, Casarin A. Point-of-care testing in the overcrowded emergency department–can it make a difference? Crit Care. 2014;18(6):692.
   PubMed Web of Science ®Google Scholar